CJC-1295 and Ipamorelin are the two halves of the most popular growth hormone peptide pairing in research. Both push the body to release more of its own growth hormone, but they do it through entirely separate doorways into the pituitary. That difference is not a reason to pick one over the other. It is the reason they work so well together.
Same goal, two different doors
Growth hormone is released by the pituitary gland under the control of two separate signalling systems. CJC-1295 works through one of them; Ipamorelin works through the other.
CJC-1295 is an analog of growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on the pituitary, the same receptor the body’s natural GHRH uses, and tells the gland to produce and release growth hormone. In its DAC form, it binds to albumin in the blood, giving it a long half-life of several days for a steady, sustained signal.
Ipamorelin is a growth hormone-releasing peptide (GHRP). It works through a completely different receptor, the ghrelin receptor (GHS-R1a), to trigger a sharp, clean pulse of growth hormone. What sets it apart from older GHRPs is its selectivity: it releases growth hormone without the unwanted spikes in cortisol and prolactin that earlier compounds caused.
What the research shows
CJC-1295’s signature is sustained elevation. In a clinical study by Walker and colleagues (2006, Journal of Clinical Endocrinology and Metabolism), CJC-1295 with DAC produced dose-dependent increases in growth hormone and IGF-1 that lasted several days from a single injection, with IGF-1 rising roughly 1.5 to 3 times above baseline.
Ipamorelin’s signature is a precise, well-tolerated pulse, valued specifically because it leaves cortisol and prolactin largely untouched and does not drive appetite at research doses.
The most important finding is what happens when they are combined: stimulating both the GHRH and the ghrelin pathways at once produces a growth hormone response greater than the sum of each alone, a well-documented effect known as GHRH+GHRP synergy.
Side-by-side comparison
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Class | GHRH analog | GHRP (ghrelin receptor agonist) |
| Receptor | GHRH receptor | GHS-R1a (ghrelin) receptor |
| GH release style | Sustained, long-lasting | Sharp, clean pulse |
| Half-life (DAC) | Several days | Short |
| Standout trait | Steady GH and IGF-1 elevation | No cortisol or prolactin spike |
| Role in the pair | The steady baseline | The selective pulse |
Why they are usually combined
Because they act on two different receptors, CJC-1295 and Ipamorelin do not compete; they stack. CJC-1295 raises the overall, sustained level of growth hormone signalling, while Ipamorelin adds a clean, selective pulse on top. Together they produce a stronger and more natural growth hormone rhythm than either alone, which is exactly why they are most often researched as the combined CJC-1295 / Ipamorelin blend rather than separately.
The bottom line
CJC-1295 and Ipamorelin reach the same destination, more of the body’s own growth hormone, through two separate doors: the GHRH receptor and the ghrelin receptor. CJC-1295 provides the sustained baseline, Ipamorelin the clean selective pulse, and together they create a synergy that outperforms either one. That synergy is why the CJC-1295 / Ipamorelin pairing is the standard in growth hormone peptide research.
References
- Walker RF, et al. CJC-1295 with DAC produces sustained increases in GH and IGF-1 in healthy adults. Journal of Clinical Endocrinology and Metabolism, 2006.
- GHRH and GHRP synergy in growth hormone secretion (mechanistic study of dual-pathway GH release, 1999).
- Ipamorelin: a selective growth hormone secretagogue with minimal cortisol and prolactin effects (receptor selectivity research).
For laboratory and research use only.